keyword
MENU ▼
Read by QxMD icon Read
search

Cooper PS

keyword
https://www.readbyqxmd.com/read/29749724/lighting-up-the-thioflavin-t-by-parallel-stranded-tg-ga-n-dna-homoduplexes
#1
Jinbo Zhu, Zhiqiang Yan, Weijun Zhou, Chuanbo Liu, Jin Wang, Erkang Wang
Thioflavin T (ThT) was once regarded to be a specific fluorescent probe for the human telomeric G-quadruplex, but more other kinds of DNA were found that can also bind to ThT in recent years. Herein, we focus on G-rich parallel-stranded DNA and utilize fluorescence, absorbance, circular dichroism and surface plasmon resonance spectroscopy to investigate its interaction with ThT. Pyrene label and molecular modelling are applied to unveil the binding mechanism. We find a new class of non-G-quadruplex G-rich parallel-stranded (ps) DNA with the sequence of TG(GA)n can bind to ThT and increase the fluorescence with an enhancement ability superior to G-quadruplex...
May 11, 2018: ACS Sensors
https://www.readbyqxmd.com/read/29747287/-a-comparative-study-of-comprehensive-geriatric-assessment-in-elder-patients-with-non-hodgkin-s-lymphoma
#2
H Liu, M Gao, D Mei, H X Han, J T Li, J F Bai, C L Zhang, R Feng, J P Wei, Y Tian, T Wang
Objective: To measure the comprehensive geriatric assessment (CGA) in elder non-Hodgkin's Lymphoma (NHL) patients in a cross-sectional study; to compare the differences between Eastern Cooperative Oncology Group (ECOG)-performance status (PS) and CGA. Methods: CGA stratification included the following 3 instrument assessments: activity of daily living (ADL);instrumental activity of daily living (IADL);comorbidity score according to the modified cumulative illness rating score for geriatrics (MCIRS-G). According to CGA and age, NHL patients, aged ≥60 years, were classified as"fit","unfit"and"frail"groups...
May 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29745736/clinical-outcome-and-prognostic-analysis-of-meningeal-carcinomatosis-treated-by-intrathecal-chemotherapy
#3
Zhaohua Meng, Qinqin Zhang, Kun Hong, Weixin Han, Zeyan Zhao, Yajuan Liu, Junying He, Hui Bu
OBJECTIVE: To evaluate the clinical efficacy of meningeal carcinomatosis (MC) treated by intrathecal chemotherapy (IC) and analyzes the prognostic factors. METHODS: The clinical and follow-up data of 33 MC patients was collected and retrospectively analyzed. Potential prognostic factors such as age, gender, primary cancer, transfer time, presence of brain metastasis, intracranial pressure, protein, glucose, vascular endothelial growth factor (VEGF), eastern cooperative oncology group (ECOG) performance status (PS), systemic treatment and IC were discussed...
May 10, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29744672/efficacy-and-safety-of-neoadjuvant-treatment-with-bevacizumab-liposomal-doxorubicin-cyclophosphamide-and-paclitaxel-combination-in-locally-regionally-advanced-her2-negative-grade-iii-at-premenopausal-status-breast-cancer-a-phase-ii-study
#4
Ekaterini C Tampaki, Athanasios Tampakis, Constantinos E Alifieris, Dimitrios Krikelis, Anastasia Pazaiti, Michalis Kontos, Dimitrios T Trafalis
BACKGROUND: In the era of personalized therapy, targeted treatment in specific patient populations is mandated. OBJECTIVE: We evaluated the efficacy and safety of neoadjuvant treatment on locally advanced breast cancer (LABC) with a monoclonal agent against vascular endothelial growth factor (VEGF), bevacizumab plus chemotherapy combination of liposomal doxorubicin, cyclophosphamide and paclitaxel (PLAC-B). METHODS: Patients enrolled were at premenopausal status and characterized by human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor positive (estrogen receptor/progesterone receptor-positive [ER/PR+]) or triple-negative (TNBC), LABC (T > 3 cm), with high-grade ductal carcinoma...
May 9, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29743951/palliative-chemotherapy-outcomes-in-patients-with-ecog-ps-higher-than-1
#5
Rafael Caires-Lima, Karolina Cayres, Bruno Protásio, Inacelli Caires, Júlia Andrade, Lucila Rocha, Tiago Kenji Takahashi, Paulo M Hoff, Gilberto de Castro, Milena Perez Mak
Purpose: Although patients with incurable disease and Eastern Cooperative Oncology Group performance status (ECOG-PS ≥ 2) are underrepresented in clinical trials, they are frequently offered palliative chemotherapy (pCT) in daily clinical practice in order to improve symptoms and quality of life. In this case-control retrospective analysis, our goal was to identify factors associated with poorer survival and lack of benefit of pCT in this population. Patients and methods: We evaluated 2,514 patients who died between August 2011 and July 2012 in an academic cancer care institution and its hospice...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29739893/trifluridine-tipiracil-tas-102-in-refractory-metastatic-colorectal-cancer-a-multicenter-register-in-the-frame-of-the-italian-compassionate-use-program
#6
Chiara Cremolini, Daniele Rossini, Erika Martinelli, Filippo Pietrantonio, Sara Lonardi, Silvia Noventa, Emiliano Tamburini, Giovanni Luca Frassineti, Stefania Mosconi, Federico Nichetti, Sabina Murgioni, Teresa Troiani, Beatrice Borelli, Gemma Zucchelli, Alessandro Dal Maso, Vincenzo Sforza, Gianluca Masi, Carlotta Antoniotti, Maria Di Bartolomeo, Rosalba Miceli, Fortunato Ciardiello, Alfredo Falcone
BACKGROUND: TAS-102 is indicated for patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, available therapies. Given the complete inefficacy in half of patients, the lack of predictive factors, the palliative setting, and the financial and clinical toxicity, optimizing the cost-benefit ratio is crucial. The "ColonLife" nomogram allows an estimate of the 12-week life expectancy of patients with refractory mCRC. MATERIALS AND METHODS: We collected data from patients treated at eight Italian centers in the compassionate use program...
May 8, 2018: Oncologist
https://www.readbyqxmd.com/read/29723866/prognostic-factors-associated-with-postprogression-survival-in-advanced-hepatocellular-carcinoma-patients-treated-with-sorafenib-not-eligible-for-second-line-regorafenib-treatment
#7
Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Isao Nakano, Yoshiki Hirooka, Hidemi Goto
OBJECTIVES: The aim of this study was to investigate the prognostic factors associated with postprogression survival (PPS) in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib, who were not eligible for second-line treatment with regorafenib. METHODS: A total of 103 patients with radiological confirmation of progressive disease (PD) were enrolled. RESULTS: The median PPS (n = 67) was 6.1 months. Significant and independent prognostic factors at initial radiological PD associated with good PPS were an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0, the absence of macrovascular invasion (MVI), and time to progression (TTP) ≥4 months...
May 3, 2018: Oncology
https://www.readbyqxmd.com/read/29721042/a-real-world-data-study-to-evaluate-treatment-patterns-clinical-characteristics-and-survival-outcomes-for-first-and-second-line-treatment-in-locally-advanced-and-metastatic-urothelial-cancer-patients-in-germany
#8
Günter Niegisch, Holger Gerullis, Shih-Wen Lin, Julie Pavlova, Adam Gondos, Anja Rudolph, Gabriele Haas, Nora Hennies, Mario W Kramer
Background : Worldwide, urothelial carcinoma (UC) is a common cause of morbidity and mortality. In particular, the incidence of bladder cancer varies widely across Europe; Germany has the ninth highest international age-standardized incidence. For advanced UC or metastatic UC (mUC), platinum-based combination chemotherapy is the standard first-line (1L) treatment; however, there is wide heterogeneity of second-line (2L) treatments, ranging from vinflunine in parts of Europe to taxanes and other agents elsewhere in Europe, in the United States and globally...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29695228/impact-of-clinical-trial-participation-on-survival-in-patients-with-castration-resistant-prostate-cancer-a-multi-center-analysis
#9
Kyo Chul Koo, Jong Soo Lee, Jong Won Kim, Kyung Suk Han, Kwang Suk Lee, Do Kyung Kim, Yoon Soo Ha, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung
BACKGROUND: Clinical trial (CT) participation may confer access to new, potentially active agents before their general availability. This study aimed to investigate the potential survival benefit of participation in investigational CTs of novel hormonal, chemotherapeutic, and radiopharmaceutical agents in patients with castration-resistant prostate cancer (CRPC). METHODS: This multi-center, retrospective analysis included 299 consecutive patients with newly diagnosed, non-metastatic or metastatic CRPC between September 2009 and March 2017...
April 26, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29682855/clinical-outcomes-of-sorafenib-treatment-failure-for-advanced-hepatocellular-carcinoma-and-candidates-for-regorafenib-treatment-in-real-world-practice
#10
Uchikawa Shinsuke, Tomokazu Kawaoka, Hiroshi Aikata, Kenichiro Kodama, Yuno Nishida, Yuki Inagaki, Masahiro Hatooka, Kei Morio, Takashi Nakahara, Eisuke Murakami, Akira Hiramatsu, Masataka Tsuge, Michio Imamura, Yoshiiku Kawakami, Kazuaki Chayama
AIM: As second-line therapy, regorafenib has been shown to provide a survival benefit for patients with hepatocellular carcinoma (HCC) who progress on sorafenib. In this retrospective study, we assessed the clinical outcomes of sorafenib treatment failure with regard to second-line chemotherapy. METHODS: Patients (N=160) with advanced HCC, Child-Pugh A liver function and Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 treated with sorafenib between June 2009 and September 2016 were enrolled...
April 22, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29680675/far-red-light-mediated-programmable-anti-cancer-gene-delivery-in-cooperation-with-photodynamic-therapy
#11
Jinhui Wang, Hua He, Xin Xu, Xiao Wang, Yongbing Chen, Lichen Yin
Effective anti-cancer therapy is hurdled by the complicated extracellular and intracellular barriers, and thus a smart gene vector that can enable programmable gene delivery is highly demanded. Photo-manipulation of gene delivery processes features spatial and temporal precision, while majority of current strategies utilizes short-wavelength UV/visible light with poor tissue penetration or high-power-density near-infrared (NIR) light that would cause undesired heat damage. Herein, an ROS-degradable polycation was designed and co-delivered with a photosensitizer (PS), thus realizing photo-programmable gene delivery using far-red light (661 nm) at low optical power density (down to 5 mW cm-2 )...
April 12, 2018: Biomaterials
https://www.readbyqxmd.com/read/29668571/evaluating-for-pseudoprogression-in-colorectal-and-pancreatic-tumors-treated-with-immunotherapy
#12
Christine M Parseghian, Madhavi Patnana, Priya Bhosale, Kenneth R Hess, Ya-Chen Tina Shih, Bumyang Kim, Scott Kopetz, Michael J Overman, Gauri R Varadhachary, Milind Javle, Aung Naing, Sarina Piha-Paul, David Hong, Hung Le, Vivek Subbiah, Shubham Pant
Pseudoprogression has been observed in patients with various tumor types treated with immunotherapy. However, the frequency of pseudoprogression is unknown in gastrointestinal malignancies. Metastatic colorectal cancer (mCRC) and advanced pancreatic ductal adenocarcinoma (PDAC) patients who progressed on treatment with immunotherapy beyond RECIST version 1.1 criteria were analyzed. Degree of progression, tumor markers, time to progression, overall survival, Eastern Cooperative Oncology Group Performance Status (ECOG PS), and costs were analyzed for patients treated beyond progression (TBP) and not treated beyond progression...
April 17, 2018: Journal of Immunotherapy
https://www.readbyqxmd.com/read/29627566/validation-of-the-simplified-chinese-version-of-the-memorial-symptom-assessment-scale-short-form-msas-sf-sc-among-cancer-patients
#13
Liang Fu, Yan Hu, Zhenqi Lu, Yingfeng Zhou, Xiaoju Zhang, Victor T Chang, Yang Yang, Yang Wang
CONTEXT: Comprehensive symptom assessment is crucial for symptom management. The Memorial Symptom Assessment Scale Short Form (MSAS-SF) has been validated for symptom assessment in cancer patients, but there is no Simplified Chinese version. OBJECTIVES: To present the validation procedures and results for the Simplified Chinese version of the Memorial Symptom Assessment Scale Short Form (MSAS-SF-SC) among cancer patients in mainland China. METHODS: The MSAS-SF was translated and culturally adapted into Simplified Chinese...
April 5, 2018: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/29625898/palliative-thoracic-radiation-therapy-for-non-small-cell-lung-cancer-2018-update-of-an-american-society-for-radiation-oncology-astro-evidence-based-guideline
#14
Benjamin Moeller, Ehsan H Balagamwala, Aileen Chen, Kimberly M Creach, Giuseppe Giaccone, Matthew Koshy, Sandra Zaky, George Rodrigues
PURPOSE: To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lung cancer. METHODS AND MATERIALS: Based on a systematic PubMed search showing new evidence for this key question, the task force felt an update was merited. Guideline recommendations were created using a predefined consensus-building methodology supported by American Society for Radiation Oncology-approved tools for grading evidence quality and recommendation strength...
April 3, 2018: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29618479/comparable-outcomes-of-patients-eligible-versus-ineligible-for-swog-leukemia-studies
#15
Abby Statler, Megan Othus, Harry P Erba, Thomas R Chauncey, Jerald P Radich, Steven Coutre, Anjali Advani, Sucha Nand, Farhad Ravandi, Sudipto Mukherjee, Mikkael A Sekeres
Patients may be deemed ineligible for a clinical trial for reasons that do not directly impact efficacy or safety. We identified and categorized reasons for ineligibility and compared outcomes of ineligible with eligible patients treated on SWOG Leukemia Committee protocols. Patients enrolled in SWOG phase II, II/III, or III protocols open since 2005 were analyzed for eligibility status, reasons for ineligibility, baseline characteristics, Eastern Cooperative Oncology Group (ECOG) performance status (PS), serious adverse events (SAEs), and outcomes, including complete remission (CR) status and overall survival (OS)...
April 4, 2018: Blood
https://www.readbyqxmd.com/read/29589391/effects-of-serum-albumin-calcium-levels-cancer-stage-and-performance-status-on-weight-loss-in-parathyroid-hormone-related-peptide-positive-or-negative-patients-with-cancer
#16
Ji Yeon Lee, Namki Hong, Hye Ryun Kim, Byung Wan Lee, Eun Seok Kang, Bong Soo Cha, Yong Ho Lee
BACKGROUND: A recent animal study showed that parathyroid hormone-related peptide (PTHrP) is associated with cancer cachexia by promoting adipose tissue browning, and we previously demonstrated that PTHrP predicts weight loss (WL) in patients with cancer. In this study, we investigated whether prediction of WL by PTHrP is influenced by clinical factors such as serum albumin, corrected calcium levels, cancer stage, and performance status (PS). METHODS: A cohort of 219 patients with cancer whose PTHrP level was measured was enrolled and followed for body weight (BW) changes...
March 2018: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29587656/erlotinib-treatment-after-platinum-based-therapy-in-elderly-patients-with-non-small-cell-lung-cancer-in-routine-clinical-practice-results-from-the-eldertac-study
#17
Wolfgang M Brueckl, H Jost Achenbach, Joachim H Ficker, Wolfgang Schuette
BACKGROUND: In this prospective non-interventional study, the effectiveness and tolerability of erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after ≥1 platinum-based chemotherapy were assessed. METHODS: A total of 385 patients ≥65 years of age with advanced NSCLC receiving erlotinib were observed over 12 months. The primary endpoint was the 1-year overall survival (OS) rate. RESULTS: Patients were predominantly Caucasian (99...
March 27, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29581983/clinical-characteristics-and-survival-outcomes-for-non-small-cell-lung-cancer-patients-with-epidermal-growth-factor-receptor-double-mutations
#18
Min Peng, Yi Ming Weng, Hua Li Liu, Gui Fang Yang, Yi Yao, Guang Han, Qi Bin Song
Multiple randomized clinical trials have demonstrated that epidermal growth factor receptor (EGFR) exon 19 deletion (19Del) and exon 21 L858R mutation (L858R) are highly correlated with sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in non-small-cell lung cancer (NSCLC). A mutation in exon 20 (T790M) is reportedly associated with resistance to EGFR-TKIs. However, few studies have focused on patients harboring double mutations in these 3 mutation sites. In this retrospective study, forty-five patients (45/2546, 1...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29581811/lymphocyte-to-monocyte-ratio-and-modified-glasgow-prognostic-score-predict-prognosis-of-lung-adenocarcinoma-without-driver-mutation
#19
Seigo Minami, Shouichi Ihara, Sung-Ho Kim, Suguru Yamamoto, Kiyoshi Komuta
Background: Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR) and modified Glasgow prognostic score (mGPS) are useful prognostic markers based on host-related systemic inflammatory response. They have been shown as independent prognostic biomarkers in various cancers, including non-small cell lung cancer. However, there has been little evidence for a specific population of pulmonary adenocarcinoma without active epidermal growth factor receptor (EGFR) mutation. Methods: We retrospectively reviewed 159 patients who met the following criteria: histologically or cytologically diagnosed adenocarcinoma, confirmed wild-type EGFR, started first-line cytotoxic chemotherapy between July 2007 and March 2017 at our hospital, and c-stage IIIB or IV...
February 2018: World Journal of Oncology
https://www.readbyqxmd.com/read/29543442/cooperative-assembly-of-magneto-nanovesicles-with-tunable-wall-thickness-and-permeability-for-mri-guided-drug-delivery
#20
Kuikun Yang, Yijing Liu, Yi Liu, Qian Zhang, Chuncai Kong, Chenglin Yi, Zijian Zhou, Zhantong Wang, Guofeng Zhang, Yang Zhang, Niveen M Khashab, Xiaoyuan Chen, Zhihong Nie
This article describes the fabrication of nanosized magneto-vesicles (MVs) comprising tunable layers of densely-packed superparamagnetic iron oxide nanoparticles (SPIONs) in membranes via cooperative assembly of polymer-tethered SPIONs and free poly(styrene)-b-poly(acrylic acid) (PS-b-PAA). The membrane thickness of MVs could be well controlled from 9.8 to 93.2 nm by varying the weight ratio of PS-b-PAA to SPIONs. The increase in membrane thickness was accompanied with the transition from monolayer MVs, to double-layered MVs and to multilayered MVs (MuMVs)...
March 15, 2018: Journal of the American Chemical Society
keyword
keyword
115948
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"